ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer

Abstract

The excision repair cross-complementation group 1 (ERCC1) and BRCA1 have been identified as predictors of clinical outcomes among patients with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. In this study, we immunohistochemically examined the ERCC1 and BRCA1 protein expression levels in 35 patients with metastatic mediastinal lymph nodes obtained prior to treatment as retrospective study. These patients had been enrolled in our studies on neoadjuvant chemotherapy with cisplatin and irinotecan (15 patients) or chemoradiotherapy with cisplatin and docetaxel plus concurrent thoracic radiation (20 patients). The relations between the ERCC1 or BRCA1 protein expression and the clinical outcomes of the patients were then examined. The rates of radiological response and pathological effectiveness were significantly higher among patients with ERCC1-negative tumors, compared with those with positive tumors in the neoadjuvant chemotherapy group (radiological response rates; 100% vs. 42.8%, P=0.013; pathological effectiveness; 100% vs. 47.1%, P=0.038), but no associations were observed in the neoadjuvant chemoradiotherapy group. Regarding survival, no significant differences in overall survival or disease-free survival were observed between patients with ERCC1-negative and positive tumors in both the neoadjuvant chemotherapy and chemoradiotherapy groups. In summary, we showed that a ERCC1-negative protein status was significantly related to tumor responsiveness to neoadjuvant chemotherapy with cisplatin and irinotecan, but such a status was not a clear prognostic predictor to cisplatin-based neoadjuvant therapy in NSCLC patients. Further study is needed to clarify the value of molecular predictors for customizing therapy for patients with NSCLC.

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

“…As an excision nuclease within the NER pathway, excision repair cross complementing group 1 (ERCC1) has been reported to play a major role in the response to platinum-based chemotherapy. Studies have shown that the higher the ERCC1 expression levels, the less sensitive the tumors to platinum therapies [4][5][6][7] . Recently, a single nucleotide polymorphism at codon 118 (C→T) was reported to be associated with altered ERCC1 mRNA levels [8] and clinical outcome in cancer patients treated with platinum-based chemotherapy [9][10][11][12] .…”

Association between Bone Marrow Hypermetabolism on18F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer

“…, 종양 조 직에서 excision repair cross-complementing 1 (ERCC1) mRNA의 발현이 항암화학요법에 대한 반응을 예측할 수 있음을 보여주는 연구도 있었다 23,24 . Epidermal growth factor receptor (EGFR) gene copy 수와 EGFR mutations 이 epidermal growth factor receptor tyrosine kinase inhibitors에 대한 결과를 예측할 수 있을 것이라는 보고가 있었다 25,26 .…”

Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer

“…Studies have shown that ERCC1, as an excision nuclease within the NER pathway, play a crucial role in response to platinum-based chemotherapy (Bramson and Panasci, 1993;Olaussen et al, 2006;Kwon et al, 2007) and overexpression of ERCC1 is correlated with less sensitive of tumor cells to platinum therapies (Kwon et al, 2007;Fujii et al, 2008). C8092A (rs3212986) is a common polymorphism of ERCC1.…”